ADAM22, a Kv1 channel-interacting protein, recruits membrane-associated guanylate kinases to juxtaparanodes of myelinated axons

Citation for published version:

Digital Object Identifier (DOI):
10.1523/JNEUROSCI.4661-09.2010

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published In:
Journal of Neuroscience

Publisher Rights Statement:
Published in final edited form as:
doi: 10.1523/JNEUROSCI.4661-09.2010

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
ADAM22, A KV1 CHANNEL INTERACTING PROTEIN, RECRUITS MAGUKS TO JUXTAPARANODES OF MYELINATED AXONS

Yasuhiro Ogawa1,†, Juan Oses-Prieto2, Moon Young Kim3, Ido Horresh4, Elior Peles4, Alma L. Burlingame2, James S. Trimmer3, Dies Meijer5, and Matthew N. Rasband1

1Department of Neuroscience, Baylor College of Medicine, Houston, TX 77030. 2Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158-2517. 3Section of Neurobiology, Physiology and Behavior, College of Biological Sciences, University of California, Davis, CA 95616. 4Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel 76100. 5Department of Cell Biology and Genetics, Erasmus MC University Medical Center, 3000 DR Rotterdam, The Netherlands.

Abstract

Clustered Kv1 K+ channels regulate neuronal excitability at juxtaparanodes of myelinated axons, axon initial segments (AIS), and cerebellar basket cell terminals (BCTs). These channels are part of a larger protein complex that includes cell adhesion molecules and scaffolding proteins. To identify proteins that regulate assembly, clustering, and/or maintenance of axonal Kv1 channel protein complexes, we immunoprecipitated Kv1.2 α subunits, then used mass-spectrometry to identify interacting proteins. We found that ADAM22 (A Disintegrin And Metalloproteinase 22) is a component of the Kv1 channel complex, and that ADAM22 co-immunoprecipitates Kv1.2 α subunits, then used mass-spectrometry to identify interacting proteins. We found that ADAM22 (A Disintegrin And Metalloproteinase 22) is a component of the Kv1 channel complex, and that ADAM22 co-immunoprecipitates Kv1.2 α subunits and the MAGUKs PSD-93 and PSD-95. When co-expressed with MAGUKs in heterologous cells, ADAM22 and Kv1 channels are recruited into membrane surface clusters. However, co-expression of Kv1.2 with ADAM22 and MAGUKs does not alter channel properties. Among all the known Kv1 channel interacting proteins, only ADAM22 is found at every site where Kv1 channels are clustered. Analysis of Caspr-null mice showed that like other previously described juxtaparanodal proteins, disruption of the paranodal junction resulted in redistribution of ADAM22 into paranodal zones. Analysis of Caspr2-, PSD-93-, PSD-95-, and double PSD-93/PSD-95-null mice showed ADAM22 clustering at BCTs requires PSD-95, but ADAM22 clustering at juxtaparanodes requires neither PSD-93 nor PSD-95. In direct contrast, analysis of ADAM22-null mice demonstrated juxtaparanodal clustering of PSD-93 and PSD-95 requires ADAM22, whereas Kv1.2 and Caspr2 clustering is normal in ADAM22-null mice. Thus, ADAM22 is an axonal component of the Kv1 K+ channel complex that recruits MAGUKs to juxtaparanodes.

Keywords

action potential; juxtaparanode; cell adhesion molecule; MAGUK; K+ channel

Address correspondence to: Dr. Matthew N. Rasband, Department of Neuroscience, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, Rasband@bcm.edu, phone: 713-798-4494; FAX: 713-798-3946.†Current address: Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo 204-8588, Japan.
INTRODUCTION

The excitable properties of neurons depend not only on the kinds of ion channels expressed in the plasma membrane, but also on the location of these channels. Among the many different ion channels expressed in the nervous system, the Kv1 channels are an excellent example of channels that are restricted to distinct subcellular locations. Mutations or diseases that disrupt clustering, localization, or composition of Kv1 channels severely compromise nervous system function and lead to conduction block, episodic ataxia, and/or epilepsies (Rasband et al., 1998; Eunson et al., 2000; Nashmi et al., 2000; Manganas et al., 2001b).

In the intact nervous system, Kv1 channels are clustered in high density at (1) the basket cell terminals (BCTs) of cerebellar pinceau where they regulate GABAergic inhibition of the Purkinje neuron efferent axon, (2) juxtaparanodes of myelinated axons where they modulate action potential propagation and dampen repetitive firing of injured and developing myelinated axons, and (3) axon initial segments (AIS) where they regulate action potential waveform, synaptic efficacy, and threshold of cortical interneurons (Wang et al., 1993; Laube et al., 1996; Vabnick and Shrager, 1998; Zhang et al., 1999; Devaux et al., 2002; Kole et al., 2007; Goldberg et al., 2008; Ogawa et al., 2008).

Kv1 channels form macromolecular protein complexes with the cell adhesion molecules (CAMs) Caspr2 and TAG-1, the membrane associated guanylate kinases (MAGUKs) PSD-93 and PSD-95, and the cytoskeletal scaffold 4.1B (Baba et al., 1999; Poliak et al., 1999; Poliak et al., 2001; Traka et al., 2002; Horresh et al., 2008). Juxtaparanodal Kv1 channel clustering depends on CAMs, but not MAGUKs (Rasband et al., 2002; Poliak et al., 2003; Traka et al., 2003; Horresh et al., 2008). In contrast, AIS Kv1 channel clustering was reported to depend on MAGUKs rather than CAMs (Ogawa et al., 2008). At BCTs neither Caspr2 nor PSD-95 is needed for channel clustering (Rasband et al., 2002). Thus, although these different axonal domains share a similar molecular organization, their mechanisms of assembly are unique.

Here, we identify ADAM22 as a component of the Kv1 channel protein complex. ADAM22 was previously reported to regulate synaptic transmission and to be a binding partner of Lgi1 (leucine-rich glioma inactivated 1), which is mutated in autosomal dominant partial epilepsy with auditory features (Fukata et al., 2006). ADAM22-null mice have profound hypomyelination in the PNS (Sagane et al., 2005). We show here that ADAM22 is highly enriched in axons at juxtaparanodes, AIS, and BCTs. We use a variety of biochemical, cell biological, and genetic approaches to begin to elucidate the role of ADAM22 at these axonal locations.

MATERIALS AND METHODS

Animals

Sprague–Dawley rats were purchased from Harlan™ Laboratories. ADAM22-, Caspr-, Caspr2-, PSD-93-, PSD-95-, and PSD-95/PSD-93 double-null mice were described previously (Migaud et al., 1998; McGee et al., 2001; Sagane et al., 2005; Horresh et al., 2008). Animals were housed at the Center for Laboratory Animal Care at the Baylor College of Medicine, at the Erasmus MC University Medical Center, and at the Weizmann Institute of Science. All experiments were performed in accordance with the National Institutes of Health guidelines for the humane treatment of animals.

Constructs

The following plasmids were used: pGW-PSD-93EGFP (a gift from Dr. Bonnie Firestein, Rutgers, NJ), pGW-PSD95 (a gift from Dr. Morgan Sheng), and RBG4-Kv1.4 (Nakahira et al., 1996), and pSCT-Adam22 G20. The pSCT-Adam22 G20 construct drives expression from...
a CMV promoter of a mouse Adam22 full-length cDNA. The carboxy terminal intracellular domain corresponds to the previously described G20 splice variant (Sagane et al., 2005).

**Antibodies**

Antibodies against Kv channel subunits antibody have been described (Rhodes et al., 1995). Mouse monoclonal anti-PSD-93 (N18/30), and anti-ADAM22 (cytoplasmic; N46/30, extracellular; N57/2) were obtained from the UC Davis/NIH NeuroMab Facility, supported by NIH grant U24NS050606 and maintained by the Department of Neurobiology, Physiology and Behavior, College of Biological Sciences, University of California, Davis, CA 95616. The mouse monoclonal anti-PSD-95 (K28/43.2) has been described (Rasband et al., 2002). Anti-GAD-65 (GAD-6) was obtained from Developmental Studies Hybridoma Bank (Iowa City, IA). Rabbit and Chicken anti-βIV spectrin antibodies were raised against synthetic peptides corresponding to amino acids 2237–2256 found in the "specific" domain (SD) of βIV spectrin. Rabbit Caspr antibody and mouse monoclonal Pan-Neurofascin antibody (L11A/41.6) have been previously described (Schafer et al., 2004). Rabbit polyclonal anti-Caspr2 antibody was purchased from United States Biological (MA). Rabbit polyclonal anti-Lgi1 and anti-Lgi4 were purchased from Abcam (Cambridge, MA). Chicken polyclonal anti-MAP2 antibody was purchased from EnCor Biotechnology Inc (Gainesville, FL). Rabbit polyclonal anti-Caspr2 antibody (GF090R) was purchased from United States Biological (MA). Rat monoclonal GFP antibody (GF090R) was purchased from Nacalai Tesque (Kyoto, Japan). NeuroTracer was purchased from Invitrogen. Secondary antibodies included Alexa-488 or -594 conjugated goat anti-mouse, Alexa-488 or-594 conjugated goat anti-rabbit, Alexa-488 conjugated goat anti-rat (Invitrogen-Molecular Probes, OR), and AMCA-conjugated goat anti-chicken (Jackson ImmunoResearch, PA).

**Immunofluorescence**

Cultured hippocampal neurons were fixed with 1% paraformaldehyde (PFA) in PBS for 15 minutes at 4 °C. Brains, spinal cords, or sciatic nerve were fixed by immersion with 4% PFA for 30 minutes at 4 °C, cryoprotected with 20% sucrose, embedded in Tissue-Tek OCT mounting medium, and frozen on dry ice powder. Blocks were cut using a cryostat (Leica) to obtain 20 μm-thick for brain and spinal cord, 8 μm-thick for sciatic nerve sections, and the sections were placed on precoated slides (Fisher scientific). Alternatively, some sections were cut using sliding blade microtome (ThermoFisher). Cultured neurons or tissue sections were blocked with 10 % normal Goat serum in PBS with 0.3% Triton X-100 for 2 hours at room temperature. Primary antibodies diluted in the blocking buffer were added at appropriate concentrations, incubated at room temperature overnight, and washed with PBS. Secondary antibodies were incubated at room temperature for 2 hours and washed with PBS. In some cases, antigen retrieval was performed by incubating tissue sections with 0.2 mg/ml pepsin (Dako) in 0.2M HCl for 10 minutes at 37°C. Sections were then rinsed and processed as described above. Fluorescence images were collected on an AxioImager (Carl Zeiss MicroImaging, Inc.) fitted with an apotome for optical sectioning, and a digital camera (AxioCam; Carl Zeiss MicroImaging, Inc.). AxioVision (Carl Zeiss MicroImaging, Inc.) acquisition software was used for collection of images. In some images, brightness levels were subsequently adjusted using Photoshop (Adobe). No other processing of the images was performed.

**Surface Clustering Assay**

Recombinant plasmids were co-transfected into COS7 cells using lipofectamine LTX according to the manufacturers instructions. The following plasmids were used: pGW-PSD-93EGFP, pGW-PSD95, RBG4-Kv1.4, and pSCT-Adam22 G20. After 18–24 hours, transfected Cells were fixed in 4% paraformaldehyde for 30 min at 4 °C in PBS. After three washes with PBS, ADAM22 ectodomain-directed antibodies were added for 1 hour at room
temperature. After three washes with PBS, cytoplasmically directed antibodies were added for 1 hour after permeabilization by 0.3 % Triton X-100 with normal goat serum and washed with PBS. Secondary antibodies were incubated at room temperature for 2 hours and washed with PBS. Fluorescence images were collected as describe above.

**Immunoprecipitation and Mass-spectrometry**

Whole rat brains were dissected and homogenized in ice-cold homogenization buffer (in mM: 320 sucrose, 1 EGTA, and 5 HEPES, pH 7.4). The homogenate was centrifuged at 1000 × g for 10 min. The supernatant was spun for 15 min at 13,000 × g, and the resulting pellet was resuspended in homogenization buffer. Detergent-resistant or solubilizing membranes were isolated by solubilizing brain membrane homogenates in 1% Triton X-100 lysis buffer (20 mM Tris-HCl, pH 8.0, 10 mM EDTA, 0.15 M NaCl, 10 mM iodoacetamide, 0.5 mM PMSF, 10 mM sodium azide, and a mixture of protease inhibitors: 2 µg/ml aprotinin, 1 µg/ml leupeptin, 2 µg/ml antipain, and 10 µg/ml benzamidine) at a concentration of 1 mg/ml protein for 1 hr on a rotator at 4°C. The resulting lysate was centrifuged at 13,000 × g for 30 min to separate the soluble and insoluble fractions. For immunoprecipitations, we used the soluble fraction as the starting material. Rabbit polyclonal or mouse monoclonal antibodies were added overnight at 4°C and precipitated for 3 h at 4°C with Protein A or Protein G Tris-acyr (Pierce). After washing seven times with 1% Triton X-100 lysis buffer, Immunoprecipitated complexes were added to 2x concentrated reducing sample buffer, boiled, and then loaded and size fractionated on SDS-polyacrylamide gels. Polyacrylamide gels were silver stained using the SilverSnap silver staining kit (Pierce). For identification of proteins by mass-spectrometry, gels were stained with Colloidal Blue Staining kit (Invitrogen). For immunoblotting, proteins were electrophoretically transferred to nitrocellulose membranes, followed by immunoblotting using mouse and/or rabbit antibodies.

**In-gel digestion**

Protein bands were excised from gels and digested in-gel with trypsin as described (Rosenfeld et al., 1992). The extracted digests were vacuum-evaporated and resuspended in 10 µl 0.1% formic acid in water

**Reverse-phase LC-MS/MS Analysis**

The digests were separated by nanoflow liquid chromatography using a 100-µm × 150-mm reverse-phase Ultra 120-µm C18Q column (Peeke Scientific, Redwood City, CA) at a flow rate of 350 nL/min in an Agilent 1100 high performance liquid chromatography system (Agilent Technologies, Inc, Santa Clara, CA). Mobile phase A was 0.1% formic acid in water, and mobile phase B was 0.1% formic acid in acetonitrile. Following equilibration of the column in 2% solvent B, approximately one-half of each digest (5 µl) was injected, and then the organic content of the mobile phase was increased linearly to 40% over 30 min and then to 50% in 3 min. The liquid chromatography eluate was coupled to a hybrid linear ion trap-Fourier transform mass spectrometer (LTQ-FT, Thermo Scientific, San Jose, CA) equipped with a nanoelectrospray ion source. Spraying was from an uncoated 15-µm-inner diameter spraying needle (New Objective, Woburn, MA). Peptides were analyzed in positive ion mode and in information-dependent acquisition mode to automatically switch between MS and MS/MS acquisition. MS spectra were acquired in profile mode using the ICR analyzer in the m/z range between 300 and 2000. For each MS spectrum, the 5 most intense multiple charged ions over a threshold of 200 counts were selected to perform CID experiments. Product ions were analyzed on the linear ion trap in profile mode. The CID collision energy was automatically set to 25%. A dynamic exclusion window of 0.5 Da was applied that prevented the same m/z from being selected for 90 s after its acquisition. Peak lists were generated using Mascot Distiller version 2.1.0.0 (Matrix Science, Boston, MA). Parameters for MS processing were
set as follow: peak half-width, 0.02; data points per Da, 100. Parameters for MS/MS data were set as follows: peak half-width, 0.02; data points per Da, 100. The peak list was searched against the rat subset of the NCBInr database as of January 2, 2008 (containing 64,988 entries) using in-house ProteinProspector version 5.2.2 (a public version is available on line). A minimal ProteinProspector protein score of 15, a peptide score of 15, minimal discriminant score threshold of 0.0 and a maximum expectation value of 0.1 were used for initial identification criteria. Carbamidomethylation and acrylamide modification of cysteine; acetylation of the N terminus of the protein; oxidation of methionine; and formation of pyro-Glu form N-term Gln were allowed as variable modifications. Peptide tolerance in searches was 40 ppm for precursor and 0.8 Da for product ions, respectively. Peptides containing two miscleavages were allowed. The number of modifications was limited to one per peptide. For identifications based on one or two peptide sequences with low expectation values, the MS/MS spectrum was reinterpreted manually by matching the observed fragment ions to a theoretical fragmentation obtained using MS Product (Protein Prospector) (Clauser et al., 1999).

Electrophysiology

COS-1 cells were transiently transfected with 0.1µg RBG4-Kv1.2 plasmids using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). A total of 1µg ADAM22 and PSD-95 (Kv1.2:ADAM22:PSD-95 = 1:5:5) or RBG4 plasmid was co-transfected with Kv1.2. In both cases, 0.4µg of Kvβ2 subunit was used to increase surface expression of Kv1.2 (Shi et al., 1996; Tiffany et al., 2000) and 0.2µg pEGFPc1 plasmid was used to identify the transfected cells under a fluorescence microscope. In independent experiments to determine the efficiency of co-transfection, when cells were co-transfected with GFP and Kv1.2, ADAM22, or PSD-95, >90% of cells expressed both proteins. When cells were co-transfected with GFP, Kv1.2, ADAM22, and PSD-95, followed by immunostaining for any three of the expressed proteins, >70% of cells were co-transfected. Thus, for any given GFP+ cell, >70% co-express Kv1.2, ADAM22, and PSD-95.

Outward potassium currents were recorded by whole-cell voltage-clamp technique with an EPC-10 amplifier (HEKA Electronik, Lambrecht, Germany). Data were sampled at 10 kHz (with the exception of C-type inactivation, which were sampled at 1 kHz), and filtered at 2.9 kHz using a digital Bessel filter. All currents were capacitance- and series-resistance compensated, and recorded at room temperature. Pipettes were pulled to give a final resistance of 2–3 MΩ when filled with pipette solution. External solution contained (in mM) 140 NaCl, 5 KCl, 2 CaCl2, 2 MgCl2, 10 Glucose, and 10 HEPES, pH 7.4. 300nM tetrodotoxin was added to block Na+ currents. Pipette solution contained (in mM) 140 KCl, 2 MgCl2, 1 CaCl2, 5 EGTA, 10 Glucose, and 10 HEPES, pH 7.2.

To see voltage-dependent current activation, cells were held at −100 mV and step depolarized to +70 mV in 10 mV increments for 200 ms with an interpulse interval of 5s. Currents were leak-subtracted by standard P/h procedure. Conductances (G) were obtained from the peak current amplitude (I) at each test potential (V) using Ohm’s law $G = I/(V - E_K)$ with a predicted Nernst potassium equilibrium potential $E_K$ of −84 mV. The normalized conductance were fitted to a standard single Boltzmann equation $G = G_{\text{max}}/(1 + \exp[−(V - V_{1/2})/k])$, where $G_{\text{max}}$ is the maximum conductance, $V_{1/2}$ is the voltage of half-maximal conductance, and $k$ represents the slope factor of the curve. For deactivation experiments, cells were first depolarized from −100 mV to +30 mV for 80 ms, and then step depolarized from −100 to 0 mV in 10 mV increments for 170 ms. C-type inactivation were recorded by depolarizing to +20 mV for 70 sec.

Patchmaster software (HEKA Electronik, Lambrecht, Germany) was used for acquisition and analysis of currents. Origin 7 software (OriginLab Corporation, Northampton, MA, USA) was used for fitting and creating figures. All data are presented as mean ± SE and statistically
significant differences were determined using unpaired two-tailed Student’s t-tests (P values <0.05).

RESULTS

ADAM22 associates with Kv1 channels and MAGUKs

To identify proteins that may regulate the function, assembly, and/or maintenance of Kv1 channel clusters, we used antibodies against Kv1.2 $\alpha$ subunits to co-immunoprecipitate interacting proteins from the Triton X-100 soluble fraction of a rat brain membrane homogenate. We then size-fractionated the immunoprecipitated proteins by 1D SDS-PAGE. Silver staining of the gel revealed many prominent bands (Fig. 1A), including IgG and Kv1.2 $\alpha$ subunits (asterisk). Previously we identified the MAGUKs PSD-93 and PSD-95 as Kv1 channel interacting proteins and these may correspond to the >90 kD bands observed on our gel (Rasband et al., 2002; Horresh et al., 2008). In a parallel experiment we stained the gel using colloidal blue and found a prominent band at ~85 kD. This band could also be observed on the silver-stained gel (Fig. 1A, arrowhead). We excised this band, and performed mass-spectrometry to determine the identity of this protein. Based on 4 unique peptides (mass spectra for 2 of these unique peptides are shown in Fig. 1B), we identified ADAM22 as a potential interacting protein (these 4 peptides cover 4.9% of the longest ADAM22 splice variant). For comparison, we also excised bands with molecular weights corresponding to Kv1.2 $\alpha$ subunits and Kv$\beta$2 $\beta$ subunits of the Kv1 K+ channel, and confirmed their identity (Kv1.2, 14 unique peptides covering 28% of the protein; Kv$\beta$2, 22 unique peptides covering 53% of the protein).

To confirm that ADAM22 is a constituent of the Kv1 K+ channel protein complex we performed immunoprecipitation reactions using mouse monoclonal antibodies against Kv1.2, PSD-93, PSD-95, ADAM22, and Pan Neurofascin. We found that with the exception of the control Pan Neurofascin antibody, each antibody could immunoprecipitate a macromolecular protein complex consisting of Kv1.2, PSD-93, PSD-95, Lgi1, and ADAM22 (Fig. 2A). The immunoblots of ADAM22 are consistent with the existence of multiple brain splice variants (Godde et al., 2007). Among the major ADAM22 splice variants expressed and detected in brain, the lowest molecular weight form is the predominant Kv1.2 interacting species (Fig. 2A). The observation that ADAM22 could co-immunoprecipitate with PSD-95 and Lgi1 is consistent with one previous report (Fukata et al., 2006). However, the major ADAM22 splice variants that interact with PSD-93 and PSD-95 were of higher molecular weight than that detected in the Kv1.2 immunoprecipitation reaction (Fig. 2A), even though Kv1.2 could also co-immunoprecipitate the MAGUKs PSD-93 and PSD-95.

As additional evidence that ADAM22 interacts with Kv1 channels and MAGUKs, we performed a surface-clustering assay (Kim et al., 1995) by co-expressing in COS cells ADAM22 with Kv1.4 channel $\alpha$ subunits alone (Fig. 2B), or ADAM22, Kv1.4, and the MAGUKS PSD-93 or PSD-95 (Figs. 2C and D). We used Kv1.4 because it colocalizes with Kv1.2 at juxtaparanodes and axon initial segments (Rasband et al., 2001; Ogawa et al., 2008), has the same PDZ-binding motif as Kv1.2, and because it is expressed more efficiently on the cell surface than Kv1.2 (Manganas et al., 2001a). When ADAM22 and Kv1.4 were expressed without MAGUKs, no surface clusters were detected (Fig. 2B; for these experiments we used an antibody directed against the ectodomain of ADAM22; see materials and methods). However, when ADAM22 and Kv1.4 were coexpressed with PSD-93 or PSD-95, large clusters containing all three proteins formed on the cell surface (Figs. 2C and D). Together, these results suggest that ADAM22 can participate in a large macromolecular protein complex with Kv1 channels through binding to MAGUKs.
**ADAM22 colocalizes with clustered Kv1 channels and MAGUKs**

To further establish that ADAM22 is part of the Kv1 channel/MAGUK protein complex in vivo, we immunostained CNS and PNS tissues using antibodies against ADAM22, Kv1.2, PSD-93, and PSD-95. In myelinated nerve fibers of the CNS (Figs. 3A–C) and PNS (Fig. 3D), ADAM22 colocalizes at juxtaparanodes with Kv1.2, PSD-93, and PSD-95 (Horresh et al., 2008). Similarly, ADAM22 colocalizes with Kv1.2 at BCTs in the cerebellum (Fig. 3E, inset) where PSD-95 is highly enriched (Fig. 3F, inset; Laube et al., 1996). In contrast, PSD-93 is expressed in Purkinje neurons rather than at BCTs (Fig. 3F). Finally, immunostaining of cultured hippocampal neurons revealed that ADAM22 could be detected at the AIS where it colocalizes with the cytoskeletal protein βIV spectrin, a highly specific marker of the AIS (Fig. 3G; Berghs et al., 2000) and Kv1.1 (Fig. 3H). Immunostaining for other Kv1 channels and PSD-93 at the AIS revealed a similar colocalization (data not shown). However, in contrast to previous reports (Fukata et al., 2006) we did not detect enrichment of ADAM22 at synapses in cultured hippocampal neurons.

A developmental analysis of juxtaparanode formation in the PNS showed that ADAM22 was present as early as postnatal day 4 (P4), which corresponded to the earliest time when Kv1 channels could be detected. Like Kv1 channels (Vabnick et al., 1999) ADAM22 was initially found to be present in paranodal regions where it colocalized with Caspr immunostaining, but then redistributed to juxtaparanodes (Fig. S1A). Analysis of BCTs in the cerebellum showed that although the βIV spectrin labeled AIS of the Purkinje neuron was readily identifiable by P14, GAD-65+, Kv1.2+, and ADAM22+ BCTs were not detected until P16-P18 (Fig. S1B). Taken together these results demonstrate that ADAM22 expression and localization is spatially and temporally correlated with that for clustered Kv1 channels.

**Kv1.2 channel properties are not altered by interaction with ADAM22 and PSD-95**

The interaction of ion channels with accessory subunits can alter channel properties (Rettig et al., 1994). To determine if PSD-95 and ADAM22 affect Kv1 channel properties we measured K+ currents from COS cells expressing GFP and Kv1.2 or GFP and Kv1.2 together with ADAM22 and PSD-95 (Fig. S2 and Fig. 4A). Currents in untransfected cells were negligible (Fig. 4A). GFP-positive transfected cells were selected for recording under a fluorescence microscope. We found that Kv1.2 currents, I–V curves, voltage-dependence of activation, and activation and deactivation constants were unaffected by co-expression of Kv1.2 with ADAM22 and PSD-95 (Fig. 4). Similarly, inactivation time constants were unaffected by co-expression of Kv1.2 with ADAM22 and PSD-95 (Table 1). Together, these results suggest ADAM22 and PSD-95 binding to Kv1.2 does not alter the channel’s electrophysiological properties.

**Differential requirement for MAGUK-dependent clustering of ADAM22 at juxtaparanodes and BCTs**

Although PSD-93 and PSD-95 co-immunoprecipitate and co-localize with Kv1 channels in neurons, and facilitate the clustering of Kv1 channels in transfected cells (Kim et al., 1995) and Fig. 2C and D), these MAGUKs are dispensable for clustering of Kv1 channels at juxtaparanodes (Horresh et al., 2008). Instead, juxtaparanodal Kv1 channel clustering depends on 1) paranodal junctions and 2) interactions with the cell adhesion molecule Caspr2. Thus, loss of paranodal junctions in Caspr −/− mice causes a redistribution of Kv1 channels into paranodal regions. Similarly, ADAM22 is also found colocalized with Kv1 channels at paranodes in Caspr −/− mice (compare Figs. 5A and 5B). Caspr2 −/− mice have a profound loss of both Kv1 channel and ADAM22 clustering (Fig. 5C). However, in the optic nerves of Caspr2 −/− mice we also found 32% of juxtaparanodes retained some ADAM22 and Kv1.2 (Fig. 5G), suggesting that other, Caspr2-independent mechanisms also exist in a subpopulation of myelinated axons that can facilitate Kv1.2 and ADAM22 clustering.
Since ADAM22 has a carboxy-terminal ‘ETSI’ PDZ binding motif and can be recruited into surface clusters with Kv1 channels when co-transfected with MAGUKs (Figs. 2C and D), rather than altering channel properties we considered whether PSD-93 and/or PSD-95 recruit ADAM22 to juxtaparanodes and BCTs. To test this possibility we examined juxtaparanodes and BCTs from PSD-93-null, PSD-95-null, and PSD-93/PSD-95-double null mice. We found that like Kv1 channels, deletion of one or both of these MAGUKs had no effect on the recruitment of ADAM22 to juxtaparanodes (Figs. 5D–F). Similarly, BCT clustering of Kv1 channels did not require PSD-93, PSD-95, or Caspr2 (Fig. 6; Rasband et al., 2002); in contrast to PSD-95, neither PSD-93 nor Caspr2 are found at BCTs. However, in contrast to juxtaparanodes, we found that loss of PSD-95, but not PSD-93 or Caspr2, abolished the BCT clustering of ADAM22 (Fig 6). Thus MAGUKs play different roles for the same protein complex depending on the cellular context: at juxtaparanodes they are dispensable, at BCTs they are required for clustering of ADAM22.

**ADAM22 is required for MAGUK clustering at juxtaparanodes**

To determine if ADAM22 contributes to the assembly of Kv1 channel protein complexes, we examined juxtaparanodes of P10 ADAM22-null mouse spinal cord and brainstem. ADAM22-null mice typically die at about P12 and have extensive peripheral hypomyelination (Sagane et al., 2005), making it difficult to examine the role of ADAM22 at BCTs and in Kv1 channel clustering in the PNS. Nevertheless, in both spinal cord and brainstem of P10 wild-type littermate controls and ADAM22-null mice we found normally clustered Kv1 channels and Caspr2 (Figs. 7A and 7B, green). Importantly, immunostaining of ADAM22-null mice showed no juxtaparanodal staining, confirming the specificity of the ADAM22 antibody (Figs. 7A and 7B). However, in contrast to Caspr2 and Kv1 channels, immunostaining for PSD-93 and PSD-95 showed that these MAGUKs could not be detected at juxtaparanodes (Figs. 7C and 7D). Together, these results suggest that while ADAM22 is not required for clustering of Kv1 channels or Caspr2, it is required for the recruitment of PSD-93 and PSD-95 to juxtaparanodes.

**ADAM22 is not required for clustering of Kv1 channels at the axon initial segment**

In cultured hippocampal neurons ADAM22 is found at the AIS where it co-localizes with Kv1 channels and markers of the AIS such as βIV spectrin (Figs. 3G and H) and ankyrinG (AnkG, not shown). However, we were unable to detect ADAM22 at the AIS in brain sections even after pepsin-mediated antigen retrieval, a method that was recently shown to be necessary to reveal AIS Kv1 channels in fixed tissues (Lorincz and Nusser, 2008a). To gain further insight into the mechanisms of Kv1 channel clustering at the AIS, we performed pepsin-mediated antigen retrieval followed by immunostaining on brain sections from WT, Caspr-, Caspr2-, ADAM22-, PSD-93-, PSD-95-, and PSD-93/PSD-95-null mice. In every genotype analyzed we found robust Kv1.2 channel immunoreactivity (green) that colocalized with AnkG (red) at the AIS (Fig. 7). These results are in contrast to our previous report that PSD-93 is required for clustering of Kv1 channels at the AIS (Ogawa et al., 2008; see discussion) and demonstrate that ADAM22 is not required for AIS clustering of Kv1.2.

**DISCUSSION**

In many neurons the restricted expression of axonal Kv1 channels regulates neurotransmitter release and action potential amplitude, duration, and firing rates. Kv1 channel surface expression and biophysical properties can be modulated by accessory cytoplasmic subunits (Rettig et al., 1994; Shi et al., 1996). Kv1 channels have also been shown to interact with a variety of cell adhesion molecules and cytoskeletal scaffolds, however the functions of some of these proteins and the mechanisms responsible for clustering Kv1 channels at distinct axonal locations remain ill defined.
We used immunoprecipitation and mass-spectrometry to identify ADAM22 as a new component of clustered Kv1 channel protein complexes. Intriguingly, among all the known Kv1 channel interacting proteins, only ADAM22 is found at every single site where Kv1 channels are clustered (Table 2; note that ADAM22 was detected at the AIS in culture, but we were unable to detect it at the AIS in brain sections, see below). Furthermore, our immunoprecipitation reactions suggest that ADAM22 splice-variants interact with different pools of Kv1 channel associated proteins. For example, Kv1 channels interact with a lower molecular weight form of ADAM22 than does PSD-93. This observation may suggest that while both Kv1 channels and PSD-93 can be detected at juxtaparanodes, they may interact with different pools of ADAM22 at these sites. Splice variant specific antibodies will be needed to test this possibility.

ADAM22 is a transmembrane protein with an extracellular disintegrin and catalytically inactive metalloproteinase domain that is thought to participate in cell-cell and cell-matrix interactions (White, 2003). ADAM22 has been the subject of much interest since mutations in an extracellular ADAM22 ligand, Lgi1, causes autosomal dominant partial epilepsy with auditory features. The basis of this epilepsy was proposed to result from disrupted binding of Lgi1 to ADAM22, an interaction that under normal conditions was reported to increase AMPA receptor-mediated synaptic transmission (Fukata et al., 2006). Since only half of families with this form of epilepsy were found to have mutations in Lgi1, ADAM22 was also investigated as an alternative candidate gene. However, corresponding mutations in ADAM22 have not been identified (Chabrol et al., 2007; Diani et al., 2008). Our antibodies against the cytoplasmic domain of ADAM22 failed to label excitatory synapses, suggesting either that ADAM22 is not found at these sites or a unique splice variant not detected by our antibody is found at excitatory synapses. Instead, we identified three main locations where ADAM22 is enriched: juxtaparanodes of myelinated axons, BCTs in the cerebellum, and the AIS of cultured hippocampal neurons. In every instance where we found ADAM22 immunoreactivity we also identified clustered Kv1 channels. It is possible that the postsynaptic targeting of ADAM22 may require additional extrinsic (e.g. Lgi1) factors not present in our cultures. Intriguingly, preliminary immunostaining experiments showed weak Lgi1 immunoreactivity at juxtaparanodes of PNS nerve fibers (MNR, unpublished results). In any case, the identification of ADAM22 as primarily a postsynaptic protein of excitatory synapses must be re-evaluated.

Experiments to define Kv1 channel interacting proteins at juxtaparanodes have shown that many of these same proteins are also enriched at the AIS and BCTs (Table 2). Proteomic efforts to elucidate Kv1 channel interacting proteins in brain identified PSD-93, PSD-95, Caspr2, Kvβ2, and Lgi1 (Rasband et al., 2002; Schulte et al., 2006). Interestingly, ADAM22 was also identified by Schulte et al. (2006), but was not investigated for its significance or biological function. However, the functional significance of Lgi1 as a putative component of the Kv1 channel protein complex remains controversial, since several reports indicate that Lgi1 is a secreted neuronal protein that interacts with ADAM22 (Senechal et al., 2005; Fukata et al., 2006; Sagane et al., 2008), while another suggests that it functions directly as a Kv1.1 associated subunit to inhibit channel inactivation by cytoplasmic, accessory Kvβ1 subunits (Schulte et al., 2006). Intriguingly, disruption of Lgi4, another ADAM22 binding partner, causes hypomyelination and deficits in axonal sorting (Bermingham et al., 2006), while ADAM22 null mice suffer from profound peripheral hypomyelination (Sagane et al., 2005). Since ADAM22 is clustered in axons after initiation of myelination, ADAM22’s role in myelination is likely distinct from its role in Kv1 channel complexes.

What is ADAM22’s function in axons? Besides its contribution to early PNS myelination, ADAM22 assembles a PSD-93 and PSD-95 based scaffold at juxtaparanodes (Table 3) likely through its PDZ binding motif. Juxtaparanodal clustering of Kv1 channels, PSD-93, PSD-95, and ADAM22 strongly depends on neuron-glia interactions mediated by the cell adhesion
molecules Caspr2 and TAG-1 (Poliak et al., 2003; Horresh et al., 2008), although some Kv1.2/ADAM22 protein complexes can assemble at juxtaparanodes without Caspr2. This observation suggests that there exist as yet unidentified compensatory and/or redundant mechanisms for Kv1 channel clustering in a subset of myelinated axons, and that ADAM22 is recruited to juxtaparanodes through interactions with Kv1 channels rather than Caspr2 (Table 3). Future experiments will be needed to determine if Kv1 channels interact directly with ADAM22, or if other scaffolding proteins mediate this interaction. Our immunoprecipitation reactions showed that only a small amount of the total Kv1.2 and PSD-93 could co-precipitate each other. Recently, Horresh et al. (2008) demonstrated that not all juxtaparanodes have PSD-93, which could account for this difference. Alternatively, PSD-93/Kv1 channel interactions may be more susceptible than PSD-95/Kv1 channel interactions to disruption under the solubilization conditions used here.

By analogy with excitatory synapses, the PSD-93/PSD-95 based scaffolds recruited by ADAM22 may play important roles in recruiting other modulatory or accessory proteins that could influence Kv1 channel properties. However, we did not observe any changes in Kv1.2 K+ channel function when ADAM22 was co-expressed with PSD-95 and Kv1.2. Since these experiments were performed by transfection of cDNAs into COS cells, it is not possible to determine if other accessory proteins, brought to the K+ channel through direct or indirect interactions with MAGUKs or ADAM22, are required for modulation of channel properties. A thorough proteomic analysis of axonal Kv1 channel complexes will be necessary to identify additional proteins that may influence Kv1 channel properties.

Opposite to the situation at juxtaparanodes, ADAM22 localization at BCTs requires PSD-95. BCTs, also referred to as cerebellar pinceau synapses, innervate the Purkinje neuron AIS and form junctions with morphological features similar to invertebrate septate junctions (Laube et al., 1996). Since Kv1.2, but not ADAM22, is found at BCTs in PSD-95 null mice, ADAM22 cannot be essential for Kv1 channel clustering at this specialized synapse. Nevertheless, ADAM22 may contribute to the function of BCTs by recruiting other proteins to the Kv1 channel complex, or by participating in the cell-cell interactions that stabilize this structure. Unfortunately, the early death of ADAM22-null mice before the formation of BCTs makes it very difficult to address this question.

The AIS and juxtaparanodes share a similar molecular composition (Table 2), although in contrast to cultured neurons, we did not detect AIS ADAM22 in brain sections. This may reflect differences in antigen presentation in brain as compared to neurons in culture. For example, Lorincz and Nusser (2008b) recently showed that robust detection of Kv1 channels at the AIS of cortical neurons in fixed brain requires pepsin-mediated antigen retrieval, but these same channels are detected in cultured hippocampal neurons without any form of antigen retrieval (Ogawa et al., 2008). We previously reported that PSD-93 is required for Kv1 channel clustering at the AIS. However, application of this newer method for detection of Kv1 channels in ADAM22- and PSD-93-null brains showed strong Kv1 channel immunoreactivity. Intriguingly, acute silencing of PSD-93 expression by short hairpin RNA interference in culture blocked the clustering of Kv1 channels (Ogawa et al., 2008), suggesting that the chronic loss of PSD-93 in PSD-93 −/− mice results in compensation or that there are redundant extrinsic interactions that can occur in the brain but not in cell culture. The idea that redundant mechanisms exist for Kv1 channel clustering may also be seen in Caspr2-null mice where a subset of juxtaparanodes still retain Kv1 channel immunoreactivity.

In summary, we have identified ADAM22 as a component of clustered Kv1 channels in three distinct axonal domains: the AIS, BCTs in the cerebellum, and juxtaparanodes of myelinated nerve fibers. The results presented here demonstrate that a dichotomy exists between the juxtaparanode and the BCT: ADAM22 recruits MAGUKs to the juxtaparanode, but a MAGUK...
recruits ADAM22 to the BCT. Our results also emphasize the need for additional experiments to elucidate the molecular mechanisms responsible for recruitment of Kv1 channel complexes to the AIS, juxtaparanodes, and BCTs (Table 3). Thus, despite similar molecular organizations, within each axonal domain unique mechanisms are used to assemble ADAM22/Kv1 channel/MAGUK-containing protein complexes.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Drs. David Bredt, Seth Grant, and Koji Sagane for kindly providing PSD-93, PSD-95, and ADAM22-null mice, respectively. YO is supported by a postdoctoral fellowship from the National Multiple Sclerosis Society. This work was supported by Mission Connect, The Dr. Miriam and Sheldon Adelson Medical Research Foundation, NIH grants NS044916 to MNR, NS034383 to JST, and by the National Multiple Sclerosis Society to EP. Mass spectrometry analysis was provided by the Bio-Organic Biomedical Mass Spectrometry Resource at UCSF (A.L. Burlingame, Director) supported by the Biomedical Research Technology Program of the NIH National Center for Research Resources, NIH NCCR P41RR001614 and NIH NCCR RR019934. MNR is a Harry Weaver Neuroscience Scholar of the National Multiple Sclerosis Society.

REFERENCES


J Neurosci. Author manuscript; available in PMC 2010 January 26.


Figure 1. ADAM22 is part of the Kv1 channel protein complex
A) Silver-stained gel of a Kv1.2 immunoprecipitate. The asterisk indicates the Kv1.2 band and the arrowhead indicates the ADAM22 band. B) Tandem mass spectra obtained from precursor ions with m/z=629.8495$^{+2}$ (top) and 719.3796$^{+2}$ (bottom), corresponding to two peptides spanning respectively the residues Leu-383 to Lys-393, and Ser-466 to Arg-479, of rat ADAM22. The observed sequence ions are labeled. Ions corresponding to neutral losses are marked with stars.
Figure 2. ADAM22 interacts with Kv1 channels, MAGUKs, and Lgi proteins

A) Immunoblot analysis of co-immunoprecipitation reactions using antibodies against Kv1.2, PSD-95, PSD-93, ADAM22, and Pan-Neurofascin (PanNF). The input lane corresponds to the detergent soluble fraction, while the remainder of the protein is shown in the insoluble fraction (insol). B) Co-transfection of ADAM22 and Kv1.4 in COS7 cells shows no surface clustering. E–F) Co-transfection of ADAM22, Kv1.4, and PSD-95 (C) or PSD-93 (D) results in the formation of large surface clusters that can be detected using antibodies directed against an extracellular epitope of ADAM22. Scale bar = 20 μm.
Figure 3. ADAM22 colocalizes with Kv1.2 and MAGUKs at juxtaparanodes, BCTs, and the AIS

A–D) Immunostaining for ADAM22 (A, D), PSD-93 (B), and PSD-95 (C) demonstrates colocalization with Kv1.2 (red) at juxtaparanodes in the CNS (A–C) and PNS (D). Caspr immunoreactivity (blue) defines the paranodal junctions. E–F) ADAM22 immunoreactivity colocalizes with Kv1.2 (E) and PSD-95 (F) at BCTs. PSD-93 (F) is enriched in somatodendritic domains of Purkinje neurons. In (E), NT (neurotracer) fluorescence indicates the location of neuronal cell bodies and shows that the BCT lies below the Purkinje neuron (inset). G) In cultured hippocampal neurons ADAM22 immunostaining (green) colocalizes with βIV spectrin (red) at the AIS, and is excluded from somatodendritic domains indicated by MAP2 immunoreactivity (blue). H) ADAM22 immunoreactivity (green) colocalizes with Kv1.1 (red)
and βIV spectrin (blue) at the AIS. Scale bar = 10 µm in A–D; 100 µm in E–F; 20 µm in E–F inset and G–H.
Figure 4. Co-expression of ADAM22 and PSD-95 with Kv1.2 does not affect the voltage-dependent activation and deactivation kinetics

A) Current traces from COS cells transfected with Kv1.2 alone (0.1 µg) (top) or in combination with ADAM22 and PSD-95 (0.5 µg each) (bottom). Voltage steps were applied from holding potential −100 to +70 mV in 10mV increments. B) I–V curve with Kv1.2 alone (filled squares) or with in combination of ADAM22 and PSD-95 (opened circle). C) Voltage-dependent activation. Lines represent the single Boltzmann fits to the mean ± SE normalized data. D) Activation constant as a function of voltage. Current traces were fitted with a single exponential function from the time they reached half level to the maximum current. E) Deactivation constant. Cells were held at −100mV and depolarized to 30mV for 80ms followed by test pulses to variable potentials from −100 to 0mV.
Figure 5. MAGUKs are not required for clustering of ADAM22 at juxtaparanodes
(A–G) Immunostaining of myelinated CNS axons for ADAM22 (green), Kv1.2 (red), and βIV spectrin or Caspr (blue) in wild-type (WT), Caspr−/−, Caspr2−/−, PDS-93−/−, PSD-95−/−, and PSD-95/PSD-93−/− mice.
Figure 6. PSD-95 is required for clustering of ADAM22 at basket cell terminals (BCTs)

(A) Immunostaining of BCTs for ADAM22 (green) and Kv1.2 (red) in PSD-95 −/−, PSD-93 −/−, PSD-93/PSD-95 double −/−, and Caspr2 −/− mice. (B) High magnification images showing immunostaining of BCTs for ADAM22 (green) and Kv1.2 (red), and Purkinje neuron AIS (βIV spectrin; blue) in PSD-95 −/−, PSD-93 −/−, PSD-93/PSD-95 −/−, and Caspr2 −/− mice. Scale bar = 10 µm.
Figure 7. ADAM22 is required for clustering of PSD-93 and PSD-95 at juxtaparanodes
Immunostaining of P10 wild-type (WT) and ADAM22-null (ADAM22−/−) myelinated spinal cord and brainstem axons. In the spinal cord nodes are identified by βIV spectrin immunoreactivity (blue). A) ADAM22 (red), Kv1.2 (green), and βIV spectrin (blue). B) ADAM22 (red), Caspr2 (green), and βIV spectrin (blue). C) PSD-93 (red), Kv1.2 (green), and βIV spectrin (blue). D) PSD-95 (red), Kv1.2 (green), and βIV spectrin (blue). Scale bar = 5 µm.
Figure 8. ADAM22 is not required for clustering of Kv1 channels at axon initial segments
Immunostaining of axon initial segments using antibodies against Kv1.2 (green) and ankyrinG (AnkG; red) in WT, Caspr −/−, Caspr2 −/−, ADAM22 −/−, PSD-93 −/−, PSD-95 −/−, and PSD-93/PSD-95 −/− mice. Scale bar = 10 µm.
## Table 1

Effects of ADAM22 and PSD-95 on Kv1.2-encoded K⁺ currents in COS cells.

<table>
<thead>
<tr>
<th>COS cells</th>
<th>Activation</th>
<th>Deactivation</th>
<th>Inactivation (C-type)</th>
<th>Steady-state inactivation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$V_{1/2}$; $k$</td>
<td>$\tau$ at 10; 40; 70mV (ms)</td>
<td>$\tau$ at -50; -20mV (ms)</td>
<td>$I_{\text{max/min}}$; $\tau_{\text{fast}}$; $\tau_{\text{slow}}$ (ms)</td>
</tr>
<tr>
<td>Kv1.2</td>
<td>7.9 ± 3.2</td>
<td>36.5 ± 5.4</td>
<td>15.3 ± 1.6</td>
<td>0.24 ± 0.03</td>
</tr>
<tr>
<td>(n=17)</td>
<td>11.5 ± 0.8</td>
<td>12.5 ± 3.6</td>
<td>23.0 ± 2.6</td>
<td>35.5 ± 1.8</td>
</tr>
<tr>
<td></td>
<td>4.17 ± 0.8</td>
<td>(n=14)</td>
<td>(n=11)</td>
<td>(n=6)</td>
</tr>
<tr>
<td>Kv1.2 +ADAM22</td>
<td>9.1 ± 5.5</td>
<td>40.7 ± 9.1</td>
<td>12.1 ± 1.8</td>
<td>4.9 ± 2.6</td>
</tr>
<tr>
<td>(n=9)</td>
<td>10.6 ± 0.5</td>
<td>10.0 ± 2.7</td>
<td>25.1 ± 3.6</td>
<td>40.0 ± 4.9</td>
</tr>
<tr>
<td>Kv1.2 +PSD−95</td>
<td>3.2 ± 0.6</td>
<td>(n=9)</td>
<td>(n=5)</td>
<td>(n=3)</td>
</tr>
<tr>
<td>(n=9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 2
Molecular composition of Kv1 channel protein complexes at sites where channels are clustered. ● = detected, ○ = not detected.

<table>
<thead>
<tr>
<th></th>
<th>Juxtaparanode</th>
<th>Axon Initial Segment</th>
<th>Basket Cell Terminal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kv1.x&lt;sup&gt;a&lt;/sup&gt;,&lt;sup&gt;b&lt;/sup&gt;</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
<tr>
<td>Kvβ2&lt;sup&gt;b&lt;/sup&gt;,&lt;sup&gt;c&lt;/sup&gt;</td>
<td>●</td>
<td>●</td>
<td>○</td>
</tr>
<tr>
<td>Caspr2&lt;sup&gt;b&lt;/sup&gt;</td>
<td>●</td>
<td>●</td>
<td>○</td>
</tr>
<tr>
<td>TAG-1&lt;sup&gt;&lt;i&gt;b&lt;/i&gt;&lt;/sup&gt;,&lt;sup&gt;d&lt;/sup&gt;</td>
<td>●</td>
<td>●</td>
<td>○</td>
</tr>
<tr>
<td>PSD-93&lt;sup&gt;b&lt;/sup&gt;</td>
<td>●</td>
<td>●</td>
<td>○</td>
</tr>
<tr>
<td>PSD-95&lt;sup&gt;b&lt;/sup&gt;</td>
<td>●</td>
<td>○</td>
<td>●</td>
</tr>
<tr>
<td>4.1B&lt;sup&gt;b&lt;/sup&gt;,&lt;sup&gt;e&lt;/sup&gt;</td>
<td>●</td>
<td>○</td>
<td>○</td>
</tr>
<tr>
<td>ADAM22</td>
<td>●</td>
<td>●</td>
<td>●</td>
</tr>
</tbody>
</table>

<sup>a</sup> Rhodes et al., 1995
<sup>b</sup> Ogawa et al., 2008
<sup>c</sup> Rasband et al., 1998
<sup>d</sup> Poliak et al., 2003
<sup>e</sup> Poliak et al., 2001
Table 3

Protein interactions that contribute to, or are required for, channel clustering. Parentheses indicate that other unidentified mechanisms can also contribute to protein clustering. N/A = not applicable.

<table>
<thead>
<tr>
<th>Clustered protein</th>
<th>Juxtaparanode</th>
<th>Axon Initial Segment</th>
<th>Basket Cell Terminal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kv1.x</td>
<td>(Caspr2)</td>
<td>(PSD-93)</td>
<td>?</td>
</tr>
<tr>
<td>Caspr2</td>
<td>TAG-1</td>
<td>?</td>
<td>N/A</td>
</tr>
<tr>
<td>PSD-93</td>
<td>ADAM22</td>
<td>?</td>
<td>N/A</td>
</tr>
<tr>
<td>PSD-95</td>
<td>ADAM22</td>
<td>N/A</td>
<td>?</td>
</tr>
<tr>
<td>ADAM22</td>
<td>Kv1.2</td>
<td>?</td>
<td>PSD-95</td>
</tr>
</tbody>
</table>

*J Neurosci.* Author manuscript; available in PMC 2010 January 26.